Clinical trial · Observational
The Galleri® Community Research Program
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
GRAIL, the company that developed the Galleri test and is sponsoring this study, would like to learn more from individuals who have received the Galleri multi-cancer early detection test. The purpose of this study is to understand how health information can be accurately collected from the medical records of individuals who have received the Galleri test in a real world setting. The collected information may include relevant medical and cancer history, diagnostic test results, including the Galleri test result. This will help GRAIL build a future larger study for individuals who have taken the Galleri test. This future study is important for understanding patient journeys after a Galleri test (including any diagnostic testing done and any diagnoses made), for improving the Galleri test, and to contribute to other research on cancer screening.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Data Collection | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Quality of data retrieved from participants who have received the Galleri test
- timeFrame
- From enrollment to the the end of study (12 month study participation period), data will be retrieved and assessed for this measure.
- description
- Data quality is measured by data completeness and accuracy of key cancer outcome data elements retrieved from medical records for confirmed cancer cases of participants who received the Galleri test.
Secondary outcomes (2)
- measure
- Data retrieval methods will be described.
- timeFrame
- From enrollment to the the end of study (12 month study participation period), data will be retrieved and assessed for this measure.
- description
- Summary of data retrieval methods, abstraction methods (e.g., manual, NLP assisted, LLM) that are used to abstract each key cancer outcome data element will be described. Additionally, the availability of each key cancer outcome data element depending on the time of abstraction following a Galleri test result will also be described.
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Have received the Galleri test prescribed by a provider per clinical care * Capable of giving signed and legally effective informed consent. Consent provided by a legally authorized representative is not permitted in this protocol. * Have signed HIPAA authorization(s)\* form for their medical records to be released and used for this study. Exclusion Criteria: * Patients are excluded from the study if the patient is a GRAIL employee or contractor. * Patients who have received the Galleri test in a GRAIL-sponsored research setting (i.e., clinical trial) are excluded.
References
Publications (0)
Data not yet available